Skip to main content
. Author manuscript; available in PMC: 2023 May 2.
Published in final edited form as: Mol Pharm. 2022 Apr 11;19(5):1378–1388. doi: 10.1021/acs.molpharmaceut.1c00924

Figure 4.

Figure 4.

Intracellular delivery of peptidyl inhibitor of Keap1. (a) Structures of CPP12-P1 and CPP12-2-P1. (b) Binding of P1, CPP12-P1 and CPP12-2-P1 to Keap1 as monitored by fluorescence polarization (FP). Keap1 (40 nM), fluorescein-labeled peptide 2 (20 nM), and increasing concentrations of P1, CPP12-P1 and CPP12-2-P1 were incubated for 1 h and FP values were measured and plotted as a function of peptide concentration. Data shown represent the mean ± SD of three independent experiments. (c) Induction of luciferase expression in HepG2-ARE (Luc) cells by P1, CPP12-P1, and CPP12-2-P1. Data shown represent the mean ± SD of n = 5 independent experiments. *, p ≤ 0.05; **, p ≤ 0.01.